ALX ONCOLOGY HOLDINGS INC. - COMMON STOCK

1,6350

14-января-25 13:05:42

15 мин. задержка

Акции

-0,0550

-3,25%

Сегодняшний диапазон

1,6100 - 1,7660

ISIN

N/A

Источник

NASDAQ

ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting

24 апр 2024 09:00:00 Источник Nasdaq GlobeNewswire
ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)

09 апр 2024 16:30:00 Источник Nasdaq GlobeNewswire
ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

07 мар 2024 15:03:00 Источник Nasdaq GlobeNewswire
ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting

05 мар 2024 15:30:00 Источник Nasdaq GlobeNewswire
ALX Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference

03 янв 2024 07:00:00 Источник Nasdaq GlobeNewswire
ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update

13 ноя 2023 15:05:01 Источник Nasdaq GlobeNewswire
ALX Oncology Announces November Investor Conference Participation

01 ноя 2023 15:05:00 Источник Nasdaq GlobeNewswire
ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

10 окт 2023 15:05:00 Источник Nasdaq GlobeNewswire
ALX Oncology Announces Pricing of Public Offering

05 окт 2023 07:00:00 Источник Nasdaq GlobeNewswire
ALX Oncology Announces Proposed Public Offering

04 окт 2023 15:10:18 Источник Nasdaq GlobeNewswire
ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

03 окт 2023 05:00:00 Источник Nasdaq GlobeNewswire
ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

02 окт 2023 15:05:00 Источник Nasdaq GlobeNewswire
ALX Oncology Realigns Executive Leadership Team

06 сен 2023 07:00:00 Источник Nasdaq GlobeNewswire
ALX Oncology Announces September Investor Conference Participation

31 авг 2023 06:00:00 Источник Nasdaq GlobeNewswire
ALX Oncology Reports Second Quarter 2023 Financial Results and Provides Clinical Program Update

10 авг 2023 15:01:00 Источник Nasdaq GlobeNewswire
ALX Oncology Receives Orphan Drug Designation from the European Commission for Evorpacept for the Treatment of Patients with Gastric Cancer

26 июн 2023 06:00:00 Источник Nasdaq GlobeNewswire
ALX Oncology Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

11 май 2023 15:01:00 Источник Nasdaq GlobeNewswire
ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Patients with Ovarian Cancer

09 май 2023 06:00:02 Источник Nasdaq GlobeNewswire
ALX Oncology Announces Clinical Trial Collaboration with Sanofi to Evaluate Evorpacept in Combination with SARCLISA (isatuximab-irfc) in Patients with Multiple Myeloma

25 апр 2023 06:00:01 Источник Nasdaq GlobeNewswire
ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce First Patient Dosed in the I-SPY-P1 TRIAL in Breast Cancer

13 мар 2023 06:00:00 Источник Nasdaq GlobeNewswire

<<
<
1
2
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.